Dyadic International Inc. (NASDAQ:DYAI) Sees Large Growth in Short Interest

by · The Markets Daily

Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 67,368 shares, an increase of 25.7% from the November 30th total of 53,615 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 793,284 shares, the days-to-cover ratio is currently 0.1 days. Based on an average trading volume of 793,284 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.3% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DYAI. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Monday. Craig Hallum began coverage on Dyadic International in a report on Monday, September 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright initiated coverage on shares of Dyadic International in a research report on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price for the company. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.00.

Get Our Latest Stock Report on Dyadic International

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its stake in Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares in the last quarter. Marathon Capital Management purchased a new position in Dyadic International in the third quarter valued at about $41,000. AlphaCore Capital LLC acquired a new position in shares of Dyadic International during the 2nd quarter worth $50,000. Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International during the 3rd quarter worth approximately $190,000. Finally, Truist Financial Corp lifted its holdings in Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares in the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Price Performance

DYAI traded up $0.06 during trading on Thursday, reaching $0.94. The company’s stock had a trading volume of 184,072 shares, compared to its average volume of 136,905. The firm has a fifty day simple moving average of $0.98 and a two-hundred day simple moving average of $0.99. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. The company has a market cap of $34.02 million, a price-to-earnings ratio of -3.92 and a beta of 1.24. Dyadic International has a 1 year low of $0.71 and a 1 year high of $2.14.

Dyadic International (NASDAQ:DYAI – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.22 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. As a group, analysts anticipate that Dyadic International will post -0.18 EPS for the current year.

Dyadic International Company Profile

(Get Free Report)

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.

Read More